Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

在其他近期新闻中，Exelixis报告了盈利、收入和分析师评估方面的显著发展。这家生物制药公司宣布，第四季度Cabo系列产品的初步销售额约为5.09亿美元，全年产品销售额约为18.05亿美元，同比增长11%。公司预计2025财年净产品销售额在19.5亿至20.5亿美元之间。

Metsera开盘价为25.5美元，较发行价上涨41.7%；收盘价为26.5美元，较发行价上涨47%；以收盘价计算，公司市值为27.81亿美元。 近期，医疗保健及生物医药企业频频在美股上市，Ascentage ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...